When prostate cancer comes back, or spreads
A rising PSA after treatment, or metastatic disease at diagnosis — the part of prostate cancer that has changed the most in a decade. The old answer was 'start hormones'; the new answer is to intensify up front, profile the genome, and sequence a growing menu of drugs.
The one-liner
A rising PSA gets restaged with PSMA-PET; early salvage radiation (PSA <0.5) is the move for local recurrence after surgery. Metastatic hormone-sensitive disease is no longer ADT alone — it's ADT plus an AR-pathway drug, with docetaxel added (a triplet) for high-volume disease. In castration-resistant disease, genomic profiling opens PARP and immunotherapy options. Spinal cord compression is the emergency.
Advanced prostate cancer is the corner of the field that has been rewritten in the last decade. Not long ago, a man whose cancer returned or spread was simply started on hormones and watched. Today the principle is the opposite: intensify early, profile the tumor, and sequence deliberatelythrough a menu that keeps growing. There are three distinct chapters here — biochemical recurrence, metastatic hormone-sensitive disease, and castration-resistant disease — and they don’t blur together.
Biochemical recurrence: a number, then a map
A PSA that climbs after definitive treatment is biochemical recurrence — ≥ 0.2 ng/mL after surgery, or nadir + 2 after radiation (the Phoenix definition). The first question is whether the cancer is back locally or has become systemic, and PSMA-PET is the imaging that answers it, lighting up disease that old CT and bone scans miss.
The PSA doubling time reads the temperament: under 9 months is aggressive, over a year is indolent. For a local recurrence after surgery, the move is salvage radiation — and timing is everything.
Salvage radiation works best when it’s early. Start it while the PSA is still below 0.5, not after it has climbed past 1 — waiting for a “bigger” number to justify treatment trades away the cure.
What everyone gets wrong
Treating metastatic hormone-sensitive disease with androgen deprivation alone. That was the standard for decades and it is now undertreatment. A long run of landmark trials showed that adding an AR-pathway inhibitor (abiraterone, apalutamide, enzalutamide) to ADT — a doublet — improves survival for essentially everyone, and that adding docetaxel on top — a triplet — helps men with high-volumedisease who are fit for chemotherapy. “Just start the ADT” leaves proven survival on the table.
Metastatic hormone-sensitive disease (mHSPC)
The framework is intensification, calibrated to disease burden:
- Doublet (ADT + AR-pathway inhibitor) — the modern baseline for metastatic hormone-sensitive disease.
- Triplet (ADT + AR-pathway inhibitor + docetaxel) — for high-volume disease (the CHAARTED definition: ≥ 4 bone metastases with at least one beyond the spine/pelvis, or visceral metastases) in a chemo-fit man.
One examiner favorite worth keeping straight: high-volume (CHAARTED, about burden) is not the same as high-risk (LATITUDE — two of: ISUP ≥ 4, ≥ 3 bone metastases, visceral disease). Different trials, different definitions.
Castration resistance: profile, then sequence
When the PSA rises despite castrate testosterone, the disease has become castration-resistant (mCRPC) — and the first move is no longer a drug but a genomic profile, because the result opens whole categories of therapy:
- HRR mutations (BRCA1/2, ATM and others) → PARP inhibitors (olaparib, talazoparib).
- MSI-high / mismatch-repair-deficient → immunotherapy (pembrolizumab).
- PSMA-positive disease after chemo → lutetium-177 PSMA radioligand therapy (VISION).
Around those sit the rest of the menu — switching the AR-pathway agent, docetaxel then cabazitaxel chemotherapy, and radium-223for symptomatic bone-only disease. The art is the order, and it’s individualized to prior treatments, genomics, and the pattern of spread.
Don't forget the body the cancer lives in
Long-term androgen deprivation has a cost — bone loss, metabolic and cardiovascular risk, sarcopenia — so bone-protective therapy (denosumab or zoledronic acid) with calcium and vitamin D, plus cardiovascular optimization, is part of the standard, not an afterthought.
And one true emergency hides in this population: spinal cord compression from vertebral metastases. New back pain with neurology in a prostate cancer patient gets dexamethasone and an urgent MRI, then radiation or surgery — treated as time-critical, because function not recovered is function lost.
If you remember one thing
The era of “just start hormones” is over. Restage a rising PSA with PSMA-PET, salvage early while the number is low, intensify metastatic hormone-sensitive disease with a doublet or triplet, and let the genome steer castration-resistant disease. And never sit on a prostate cancer patient with new back pain and weak legs.